\
&
Contact us
\
&
Contact us
This was 1 year ago
LocationBrussels
EFPIA, EUREGHA & Cancer Patients Europe are organising an event that will focus on developing a roadmap at country level to address the growing burder of cancer in Europe.
The event aims to bring together various stakeholders such as policymakers, regional health authorities, patient advocates, and healthcare providers. Through an exchange on the opportunities for health systems and the tangible benefits for patients, as well as an exploration of the challenges in translating research into practical solutions, the event will spotlight successful EU initiatives and regional approaches to uptake precision oncology.
Among the speakers:
- Szymon Bielecki: Team Leader - EU policies, Unit H.3., eHealth, Well-Being and Ageing, DG CONNECT
- Jolien Roovers: partner in EP PerMed, leading the work on accelerating innovation on personalised medicine; Policy Advisor, Flemish government, Department Economy, Science & Innovation, Research Department
- Marc van den Bulcke: Project Coordinator CAN.Heal, Sciensano
- dr. Frederick Thielen: HEcoPerMed, Assistant professor, Health Technology Assessment (HTA), Erasmus School of Health Policy & Management, Erasmus University Rotterdam
- Antonella Cardone: CEO, Cancer Patients Europe
More information, the detailed agenda and registration on the EFPIA website.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
